Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Reset

23 trials match this view; 29 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 950 across 23 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

201711
201811
202022
202122
202377
202455
202533
202622

Current indexed registry status

Completed77
Recruiting66
Active, not recruiting55
Withdrawn33
Terminated11
Unknown status11

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Countries with reported trial locations

Canada4141

Sponsors recorded in this index

Matching trial records

23 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

NCT06247839

Major Depressive Disorder
Sharmin Ghaznavi

PHASE3

Recruiting

Registry updated 2026-08-13

20

ESTIMATED

2024-09-10
2028-06-30
2028-06-30
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

NCT06820723

Depression · Anxiety · Major Depressive Disorder
Ohio State University

PHASE2

Recruiting

Registry updated 2026-07-23

40

ESTIMATED

2026-08-01
2028-09
2028-11
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial

NCT07703722

Major Depressive Disorder · Post-Traumatic Stress Disorder (PTSD)
Khyber Medical University Peshawar

PHASE3

Recruiting

Registry updated 2026-07-14

60

ESTIMATED

2026-04-01
2027-10-22
2027-11-22
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)

NCT06341426

Major Depressive Disorder · Depression · Treatment-Resistant Depression · Mood Disorders
University Health Network, Toronto

PHASE2

Active, not recruiting

Registry updated 2026-07-09

92

ESTIMATED

2024-02-05
2026-07-28
2026-12-28
Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial

NCT06230757

Major Depressive Disorder · Anhedonia · Treatment Resistant Depression
University of Colorado, Denver

PHASE2

Completed

Registry updated 2026-05-22

20

ACTUAL

2024-07-08
2026-05-08
2026-05-08
Psilocybin-assisted Cognitive Behavioral Therapy for Depression

NCT05227612

Major Depressive Disorder
University of California, Los Angeles

PHASE1

Completed

Registry updated 2026-05-19

16

ACTUAL

2023-06-27
2025-09-12
2025-09-12
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer

NCT05947383

Cancer · Major Depressive Disorder
Sunstone Medical

PHASE2

Active, not recruiting

Registry updated 2026-05-06

56

ESTIMATED

2023-10-23
2027-04-30
2027-11-01
A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control

NCT04353921

Major Depressive Disorder
Usona Institute

Phase not reported

Terminated

Registry updated 2026-05-04

26

ACTUAL

2020-06-30
2022-10-18
2022-10-18
Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression

NCT06072898

Depressive Disorder · Major Depressive Disorder
Sunnybrook Health Sciences Centre

PHASE2

Recruiting

Registry updated 2026-03-30

50

ESTIMATED

2025-05-28
2028-05
2029-05
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759

Major Depressive Disorder · Alcohol Use Disorder
Johns Hopkins University

PHASE2

Active, not recruiting

Registry updated 2026-03-13

90

ESTIMATED

2021-04-14
2026-03-02
2027-03-30
Microdosing Psychedelics to Improve Mood

NCT05259943

Major Depressive Disorder
Rotem Petranker

PHASE2

Completed

Registry updated 2025-12-30

39

ACTUAL

2023-07-15
2024-12-21
2025-02-01
An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder

NCT05399498

Borderline Personality Disorder · Major Depressive Disorder
University of Chicago

PHASE2

Completed

Registry updated 2025-12-23

9

ACTUAL

2023-11-01
2025-12-01
2025-12-01
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder

NCT06132178

Treatment Resistant Depression · MDD · Major Depressive Disorder · Recurrent Depression · Depression
University of Texas at Austin

PHASE2

Recruiting

Registry updated 2025-11-26

100

ESTIMATED

2025-01-10
2029-12-31
2030-12-31
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

NCT03554174

Major Depressive Disorder
Yale University

PHASE1

Active, not recruiting

Registry updated 2025-11-05

18

ESTIMATED

2018-02-27
2021-07-08
2026-09
Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial

NCT06746441

Major Depressive Disorder
Khyber Medical University Peshawar

PHASE2

Completed

Registry updated 2025-09-02

60

ACTUAL

2024-12-01
2025-06-01
2025-07-30
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

NCT05733546

Major Depressive Disorder
COMPASS Pathways

PHASE2

Active, not recruiting

Registry updated 2025-08-19

102

ACTUAL

2023-01-30
2025-09
2025-09
Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder

NCT06592833

Major Depressive Disorder
Icahn School of Medicine at Mount Sinai

PHASE2

Recruiting

Registry updated 2025-05-14

60

ESTIMATED

2025-02-25
2028-03-01
2028-03-01
Psilocybin for the Treatment of Major Depressive Disorder

NCT05675800

Major Depressive Disorder
Washington University School of Medicine

PHASE2

Withdrawn

Registry updated 2024-07-25

0

ACTUAL

2024-01-01
2025-01-01
2025-03-31
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study

NCT04630964

Major Depressive Disorder · Depression
Section for Affective Disorders; Northern Stockholm Psychiatry

PHASE2

Completed

Registry updated 2024-04-19

35

ACTUAL

2021-01-01
2023-04-19
2024-04-18
Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)

NCT05594667

Depression · Major Depressive Disorder · Mild Depression · Moderate Depression · Depressive Disorder
Cybin Therapeutics Inc.

PHASE2

Withdrawn

Registry updated 2023-07-06

0

ACTUAL

2023-01-01
2023-03-14
2023-03-14
SV2A Marker of Synaptogenesis in a Clinical Trial of Psilocybin for Depression

NCT05601648

Major Depressive Disorder · Anhedonia
Washington University School of Medicine

PHASE2

Withdrawn

Registry updated 2023-01-30

0

ACTUAL

2023-07-01
2025-01-01
2025-07-01
Effects of Psilocybin in Major Depressive Disorder

NCT03181529

Major Depressive Disorder
Johns Hopkins University

PHASE2

Completed

Registry updated 2021-12-15

27

ACTUAL

2017-08-10
2020-12-02
2020-12-02
The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

NCT04593563

Major Depressive Disorder
Maryland Oncology Hematology, PA

PHASE2

Unknown status

Registry updated 2021-10-15

30

ACTUAL

2020-09-01
2022-10
2023-10

Reported research facilities

Athinoula A. Martinos Center for Biomedical ImagingCharlestown, Massachusetts, United States
The Ohio State University Department of PsychiatryColumbus, Ohio, United States
Institute of Health Science, Khyber Medical UniversityIslamabad, Capital, Pakistan
Hayatabad Medical Complex PeshawarPeshawar, KPK, Pakistan
Khyber Medical UniversityPeshawar, KPK, Pakistan
Toronto Western HospitalToronto, Ontario, Canada
Centre for Addiction and Mental Health (CAMH)Toronto, Ontario, Canada
University of Colorado Anschutz Medical CampusAurora, Colorado, United States
UCLA Semel InstituteLos Angeles, California, United States
Sunstone Medical, PCRockville, Maryland, United States
Innovative Clinical Research, Inc. (formerly Segal Trials)Lauderhill, Florida, United States
Sunnybrook Health Sciences CentreToronto, Ontario, Canada
Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States
Psych ResearchToronto, Ontario, Canada
University of ChicagoChicago, Illinois, United States
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600Austin, Texas, United States
VA Connecticut Healthcare System, West Haven CampusWest Haven, Connecticut, United States
Lady Reading Hospital, PakistanPeshawar, Khyber Pakhtunkhwa, Pakistan
Kadima Neuropsychiatry InstituteLa Jolla, California, United States
Clinical Neuroscience Solutions IncJacksonville, Florida, United States
Sunstone TherapiesRockville, Maryland, United States
Elixia MA, LLCSpringfield, Massachusetts, United States
Aims TrialPlano, Texas, United States
Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy ResearchNew York, New York, United States
Northern Stockholm Spychiatry ClinicStockholm, Sweden
Centre for Neurology Studies x UpstreamAbbotsford British Columbia, British Columbia, Canada
Washington University School of MedicineSt Louis, Missouri, United States
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical CenterBaltimore, Maryland, United States
Maryland Oncology Hematology PARockville, Maryland, United States

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.